Literature DB >> 9521143

Evaluation of previously assigned antibody concentrations in pneumococcal polysaccharide reference serum 89SF by the method of cross-standardization.

N Concepcion1, C E Frasch.   

Abstract

An enzyme-linked immunosorbent assay (ELISA) and the antibody concentrations assigned to different pneumococcal capsular polysaccharide types were used to estimate concentrations of antibody to additional pneumococcal types in reference serum 89SF and to confirm assigned antibody values. This was possible because the slopes of curves of antibody binding to all polysaccharide types evaluated (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F) were similar. The point estimates for total anti-pneumococcal antibody and immunoglobulin G (IgG) antibody determined by cross-standardization by an ELISA based on use of methylated human serum albumin (mHSA) to improve the efficiency of polysaccharide binding to the ELISA plate differed by less than 40% from those reported by Quataert et al. (Clin. Diagn. Lab. Immunol. 2:590-597, 1995) for types 1, 4, 6B, 7F, 9V, 14, 18C, and 23F. However, large differences were found between the assigned values and those obtained by our mHSA ELISA for types 3 and 19F. The mHSA ELISA and the direct polysaccharide coat ELISA may not measure antibodies to the same epitopes on polysaccharides of types 3 and 19F. The functional importance of these different antibody specificities is being investigated. We have thus confirmed the assigned IgG antibody values for most types by a different method and have extended antibody assignments to several additional types.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521143      PMCID: PMC121358          DOI: 10.1128/CDLI.5.2.199-204.1998

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  13 in total

Review 1.  Evaluation of bacterial polysaccharide immune globulin for the treatment or prevention of Haemophilus influenzae type b and pneumococcal disease.

Authors:  G R Siber; C Thompson; G R Reid; J Almeido-Hill; B Zacher; M Wolff; M Santosham
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

2.  Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine.

Authors:  H Peltola; H Käyhty; M Virtanen; P H Mäkelä
Journal:  N Engl J Med       Date:  1984-06-14       Impact factor: 91.245

3.  Covalent linkage between the capsular polysaccharide and the cell wall peptidoglycan of Streptococcus pneumoniae revealed by immunochemical methods.

Authors:  U B Sørensen; J Henrichsen; H C Chen; S C Szu
Journal:  Microb Pathog       Date:  1990-05       Impact factor: 3.738

4.  Serum antibodies to pneumococcal C polysaccharide in children: response to acute pneumococcal otitis media or to vaccination.

Authors:  M Koskela
Journal:  Pediatr Infect Dis J       Date:  1987-06       Impact factor: 2.129

5.  Involvement of phospholipid end groups of group C Neisseria meningitidis and Haemophilus influenzae type b polysaccharides in association with isolated outer membranes and in immunoassays.

Authors:  G Arakere; A L Lee; C E Frasch
Journal:  J Bacteriol       Date:  1994-02       Impact factor: 3.490

6.  Epidemiology of invasive pneumococcal disease in southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial.

Authors:  K M Zangwill; C M Vadheim; A M Vannier; L S Hemenway; D P Greenberg; J I Ward
Journal:  J Infect Dis       Date:  1996-10       Impact factor: 5.226

7.  Antibody response of adults to an aluminum hydroxide-adsorbed Neisseria meningitidis serotype 2b protein-group B polysaccharide vaccine.

Authors:  C E Frasch; J M Zahradnik; L Y Wang; L F Mocca; C M Tsai
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

8.  Comparisons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by enzyme-linked immunosorbent assay.

Authors:  B D Plikaytis; S H Turner; L L Gheesling; G M Carlone
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

9.  Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay.

Authors:  L L Gheesling; G M Carlone; L B Pais; P F Holder; S E Maslanka; B D Plikaytis; M Achtman; P Densen; C E Frasch; H Käyhty
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

Review 10.  Assessment of the antibody response to pneumococcal vaccine in high-risk populations.

Authors:  S H Landesman; G Schiffman
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr
View more
  30 in total

1.  Assignment of additional anticapsular antibody concentrations to the Neisseria meningitidis group A, C, Y, and W-135 meningococcal standard reference serum CDC1992.

Authors:  Cheryl M Elie; Patricia K Holder; Sandra Romero-Steiner; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

2.  An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study.

Authors:  B D Plikaytis; D Goldblatt; C E Frasch; C Blondeau; M J Bybel; G S Giebink; I Jonsdottir; H Käyhty; H B Konradsen; D V Madore; M H Nahm; C A Schulman; P F Holder; T Lezhava; C M Elie; G M Carlone
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

Review 3.  Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.

Authors:  Catherine M Wernette; Carl E Frasch; Dace Madore; George Carlone; David Goldblatt; Brian Plikaytis; William Benjamin; Sally A Quataert; Steve Hildreth; Daniel J Sikkema; Helena Käyhty; Ingileif Jonsdottir; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

4.  Method for simultaneous measurement of antibodies to 23 pneumococcal capsular polysaccharides.

Authors:  Raymond E Biagini; Sonela A Schlottmann; Deborah L Sammons; Jerome P Smith; John C Snawder; Cynthia A F Striley; Barbara A MacKenzie; David N Weissman
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

5.  Evaluation of serum bactericidal antibody assays for Haemophilus influenzae serotype a.

Authors:  Nadine G Rouphael; Sarah Satola; Monica M Farley; Karen Rudolph; Daniel S Schmidt; Patricia Gomez-de-León; John B Robbins; Rachel Schneerson; George M Carlone; Sandra Romero-Steiner
Journal:  Clin Vaccine Immunol       Date:  2010-12-22

6.  Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(f).

Authors:  Sally A Quataert; Kate Rittenhouse-Olson; Carol S Kirch; Branda Hu; Shelley Secor; Nancy Strong; Dace V Madore
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

7.  Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.

Authors:  Haijun Tian; Avi Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

8.  Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.

Authors:  F M Russell; J R Carapetis; R L Burton; J Lin; P V Licciardi; A Balloch; L Tikoduadua; L Waqatakirewa; Y B Cheung; M L K Tang; M H Nahm; E K Mulholland
Journal:  Vaccine       Date:  2010-10-31       Impact factor: 3.641

Review 9.  Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types.

Authors:  Christine Roberts; Tina Green; Erica Hess; Katie Matys; Martha J Brown; Richard M Haupt; Alain Luxembourg; Scott Vuocolo; Alfred Saah; Joseph Antonello
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Estimation of group B streptococcus type III polysaccharide-specific antibody concentrations in human sera is antigen dependent.

Authors:  R Bhushan; B F Anthony; C E Frasch
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.